PL357379A1 - Zastosowanie chemicznych środków leczniczych - Google Patents

Zastosowanie chemicznych środków leczniczych

Info

Publication number
PL357379A1
PL357379A1 PL00357379A PL35737900A PL357379A1 PL 357379 A1 PL357379 A1 PL 357379A1 PL 00357379 A PL00357379 A PL 00357379A PL 35737900 A PL35737900 A PL 35737900A PL 357379 A1 PL357379 A1 PL 357379A1
Authority
PL
Poland
Prior art keywords
halo
alkyl
optionally substituted
optionally
topical
Prior art date
Application number
PL00357379A
Other languages
English (en)
Other versions
PL205148B1 (pl
Inventor
Hans-Herrmann Schulz
Gunther Schlimbach
Original Assignee
Hans-Herrmann Schulz
Gunther Schlimbach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7934136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL357379(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hans-Herrmann Schulz, Gunther Schlimbach filed Critical Hans-Herrmann Schulz
Publication of PL357379A1 publication Critical patent/PL357379A1/pl
Publication of PL205148B1 publication Critical patent/PL205148B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/50—Preparations specially adapted for dental root treatment
    • A61K6/54—Filling; Sealing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/60—Preparations for dentistry comprising organic or organo-metallic additives
    • A61K6/69—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Materials For Medical Uses (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL357379A 1999-12-22 2000-12-22 Zastosowanie chemicznych środków leczniczych PL205148B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19962470A DE19962470A1 (de) 1999-12-22 1999-12-22 Verwendung von Chemotherapeutika

Publications (2)

Publication Number Publication Date
PL357379A1 true PL357379A1 (pl) 2004-07-26
PL205148B1 PL205148B1 (pl) 2010-03-31

Family

ID=7934136

Family Applications (2)

Application Number Title Priority Date Filing Date
PL357379A PL205148B1 (pl) 1999-12-22 2000-12-22 Zastosowanie chemicznych środków leczniczych
PL387061A PL209943B1 (pl) 1999-12-22 2000-12-22 Zastosowanie moksifloksacyny stanowiącej kwas 1-cyklopropylo-6-fluoro-1,4-dihydro-8-metoksy-7-[(4aS,7aS)-oktahydro-6H-pirolo [3,4-b]pirydyn-6-ylo]-4-okso-3-chinolino-karboksylowy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL387061A PL209943B1 (pl) 1999-12-22 2000-12-22 Zastosowanie moksifloksacyny stanowiącej kwas 1-cyklopropylo-6-fluoro-1,4-dihydro-8-metoksy-7-[(4aS,7aS)-oktahydro-6H-pirolo [3,4-b]pirydyn-6-ylo]-4-okso-3-chinolino-karboksylowy

Country Status (21)

Country Link
US (5) US8975275B2 (pl)
EP (2) EP1244434B1 (pl)
JP (1) JP5414138B2 (pl)
KR (1) KR100803442B1 (pl)
CN (2) CN100488950C (pl)
AT (2) ATE261722T1 (pl)
AU (1) AU784496B2 (pl)
BR (1) BR0017041A (pl)
CA (2) CA2395459C (pl)
CY (1) CY1106977T1 (pl)
DE (3) DE19962470A1 (pl)
DK (2) DK1244434T3 (pl)
ES (2) ES2291583T5 (pl)
IL (2) IL150359A0 (pl)
MX (1) MXPA02006248A (pl)
NO (2) NO323727B1 (pl)
PL (2) PL205148B1 (pl)
PT (2) PT1408034E (pl)
TR (1) TR200401396T4 (pl)
WO (1) WO2001045679A2 (pl)
ZA (1) ZA200205027B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6740664B2 (en) 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
DE19962470A1 (de) 1999-12-22 2001-07-12 Schulz Hans Herrmann Verwendung von Chemotherapeutika
CA2512199A1 (en) * 2002-12-31 2004-07-15 Wockhardt Limited Compositions of benzoquinolizine carboxylic acid antibiotic drug
AU2003302305A1 (en) * 2002-12-31 2004-07-22 Sachin S Bhagwat Benzoquinolizine-2-carboxylic acid-containing compositions
NZ541681A (en) 2003-02-10 2009-02-28 Bayer Healthcare Ag Treatment of bacterial diseases of the respiratory organs by locally applying ciprofloxacin and its salts
DE10337191A1 (de) * 2003-08-13 2005-03-17 Bayer Healthcare Ag Neue Verwendung von Chinolon-Antibiotika
PL1666477T3 (pl) * 2003-09-10 2013-11-29 Kyorin Seiyaku Kk Pochodna kwasu 7-(4-podstawionego-3-cyklopropyloaminometylo-1- pirolidynylo)chinolonokarboksylowego
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same
US20090169585A1 (en) * 2003-10-23 2009-07-02 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity
US7759362B2 (en) 2004-04-21 2010-07-20 Institut Of Medicinal Biotechnology Chinese Academy Of Medical Sciences Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof
CN1244582C (zh) 2004-04-21 2006-03-08 中国医学科学院医药生物技术研究所 喹诺酮羧酸类化合物及其制备方法和医药用途
WO2006134431A1 (en) * 2005-05-03 2006-12-21 Ranbaxy Laboratories Limited Formate salt of gemifloxacin
EP1962861A2 (en) * 2005-08-26 2008-09-03 Emory University Compounds and methods for modulating the silencing of a polynucleotide of interest
DE102005045145B4 (de) * 2005-09-15 2025-09-25 Schülke & Mayr GmbH Verwendung von Octenidindihydrochlorid in halbfesten Zubereitungen
WO2008048289A2 (en) 2005-11-14 2008-04-24 University Of Maryland Biotechnology Institute Off. Of Research Admin./Tech. Dev. Salmonella based oral vaccines for anthrax
DE102006029500A1 (de) * 2006-06-27 2008-01-03 Schulz, Hans H. Verwendung einer antimikrobiellen härtenden Alginatmasse zur topischen Behandlung von Wunden und Entzündungen in der Human-, Zahn- und Veterinärmedizin
DE102007040569A1 (de) 2007-08-28 2009-03-05 Schulz, Hans H. Verfahren zur Prophylaxe von Karies und Parodontopathien
DE102008022086A1 (de) 2008-05-05 2009-11-12 Schulz, Hans H. Zweikomponenten-Alginat
EP2409702A1 (en) 2010-07-21 2012-01-25 Bayer Innovation GmbH Combination of siloxane and active ingredient for treating dental disorder of hard tissues
WO2013074948A1 (en) 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
CN103087042B (zh) * 2012-03-09 2015-02-18 南京优科生物医药有限公司 西他沙星的盐及制药用途
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) * 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
CN113559105B (zh) 2014-01-29 2026-06-23 维奥姆治疗有限公司 抗性痤疮的治疗
JP6644709B2 (ja) * 2014-04-29 2020-02-12 デンツプライ シロナ インコーポレーテッド 長期間薬物送達システムによる歯内療法
WO2018148455A1 (en) * 2017-02-08 2018-08-16 HKL Medical, LLC Intrasite administration and dosing methods and pharmaceuticals for use therein
CA3067188A1 (en) * 2017-06-16 2018-12-20 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess
WO2019136022A1 (en) * 2018-01-02 2019-07-11 New York University Periodontal disease therapy
PH12022550774A1 (en) * 2019-10-23 2023-05-03 Taigen Biotechnology Co Ltd Quinolone carboxylic acid derivatives
US20250057814A1 (en) * 2023-08-14 2025-02-20 Samer M. Ebeid Endodontic biofilm-eradication technique utilizing a dual-system intracanal medication
EP4717281A1 (de) 2024-09-30 2026-04-01 Justus-Liebig-Universität Gießen, Körperschaft des öffentlichen Rechts Antimikrobielle zubereitung

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2387647A1 (fr) * 1977-04-20 1978-11-17 Spad Lab Pate de traitement endodontique pour l'obturation canalaire de dents
EP0035073B1 (de) * 1980-02-28 1984-06-13 BBC Aktiengesellschaft Brown, Boveri & Cie. Ventil mit einer Einrichtung zur Dämpfung von durch das Arbeitsmedium selbsterregten akustischen Schwingungen
NO156828C (no) † 1980-11-10 1987-12-02 Otsuka Pharma Co Ltd Analogifremgangsm te for fremstilling av antibakterielt virksomme benzoheterocykliske forbindelser.
JPH089597B2 (ja) * 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
US4919939A (en) * 1986-04-29 1990-04-24 Pharmetrix Corporation Periodontal disease treatment system
DE3635453A1 (de) 1986-08-07 1988-02-11 Hoechst Ag Antibakterielle klebefolie
JPS6343668A (ja) 1986-08-07 1988-02-24 ヘキスト・アクチエンゲゼルシヤフト 抗細菌接着フイルムおよびその製造方法
DE3632222A1 (de) * 1986-09-23 1988-04-07 Bayer Ag Topisch anwendbare zubereitungen von gyrase-inhibitoren
JP2558107B2 (ja) 1986-12-18 1996-11-27 第一製薬株式会社 外用剤
DE3704907A1 (de) 1987-02-17 1988-08-25 Bayer Ag Topisch anwendbare zubereitungen von gyrase-inhibitoren in kombination mit kortikosteroiden
EP0286802B1 (en) * 1987-02-26 1993-06-23 Rohto Pharmaceutical Co., Ltd. Use of ofloxacin in treating or preventing locally periodontal disease
US5591744A (en) * 1987-04-16 1997-01-07 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
JPH0737385B2 (ja) 1989-01-18 1995-04-26 大塚製薬株式会社 外用抗菌剤
US5164402A (en) * 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
US5114718A (en) 1990-09-20 1992-05-19 The Procter & Gamble Company Sustained release compositions for treating periodontol disease
US5620700A (en) * 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
FR2681863B1 (fr) 1991-09-27 1995-02-03 Rhone Dpc Europ Solution de sparfloxacine sa preparation et sel la constituant.
TW209865B (pl) * 1992-01-10 1993-07-21 Bayer Ag
JP2913241B2 (ja) 1993-01-29 1999-06-28 富山化学工業株式会社 徐放性口腔用軟膏
CA2153553A1 (en) 1994-07-13 1996-01-14 Hidekazu Suzuki Stable lipid emulsion
KR19990022524A (ko) * 1995-06-06 1999-03-25 웨인스톡 스티븐 에프. 퀴놀리지논형화합물
IT1280428B1 (it) * 1995-07-14 1998-01-20 R R A S R L Composizione farmaceutica per uso topico
CN1116905C (zh) * 1995-09-14 2003-08-06 高景曦 喹诺酮杀菌消炎止血纱布
CN1155382A (zh) * 1995-11-29 1997-07-30 董重里 广谱杀菌消毒剂
DE69739215D1 (de) † 1996-05-20 2009-03-05 Otsuka Pharma Co Ltd Heilmittel fuer rosazla
JP3378772B2 (ja) 1997-06-23 2003-02-17 松下電工株式会社 コンクリート製円筒管の製造方法
KR100219327B1 (ko) 1997-08-09 1999-09-01 이서봉 퀴놀론 카르복실산 유도체
US20020037260A1 (en) * 1997-10-16 2002-03-28 Budny John A. Compositions for treating biofilm
US6017912A (en) * 1998-02-27 2000-01-25 Bussell; Letantia Topical fluoroquinolone antibiotics in an alcohol and acetone vehicle
DE19814133A1 (de) * 1998-03-30 1999-10-07 Espe Dental Ag Selbstdesinfizierende Kunststoffe und ihre Verwendung im dentalen und dentaltechnischen Bereich
AR020661A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
AU6275999A (en) 1998-09-30 2000-04-17 Alcon Laboratories, Inc. Antibiotic compositions for treatment of the eye, ear and nose
CN1072498C (zh) * 1998-11-12 2001-10-10 毛和平 一种治疗人体烧伤、烫伤的外用药
CN1072499C (zh) * 1998-12-28 2001-10-10 毛和平 一种治疗人体体表慢性溃疡的外用药
US6262071B1 (en) * 1999-06-29 2001-07-17 Smithkline Beecham Corporation Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria
DE19962470A1 (de) 1999-12-22 2001-07-12 Schulz Hans Herrmann Verwendung von Chemotherapeutika
DE10347090A1 (de) * 2003-10-10 2005-05-04 Bayer Cropscience Ag Synergistische fungizide Wirkstoffkombinationen
EP1563731A1 (en) * 2004-02-12 2005-08-17 Bayer CropScience S.A. Fungicidal composition comprising a pyridylethylbenzamide derivative and a compound capable of inhibiting the ergosterol biosynthesis
JP5271229B2 (ja) 2009-10-05 2013-08-21 大道産業株式会社 濾過システム

Also Published As

Publication number Publication date
PT1408034E (pt) 2007-11-15
CA2717246A1 (en) 2001-06-28
DK1408034T4 (da) 2011-08-15
IL150359A0 (en) 2002-12-01
ATE261722T1 (de) 2004-04-15
IL150359A (en) 2007-12-03
EP1408034A1 (de) 2004-04-14
US8975275B2 (en) 2015-03-10
AU784496B2 (en) 2006-04-13
PL209943B1 (pl) 2011-11-30
US20140287028A1 (en) 2014-09-25
NO323727B1 (no) 2007-07-02
EP1408034B2 (de) 2011-05-25
KR20020063257A (ko) 2002-08-01
JP5414138B2 (ja) 2014-02-12
CN1668598A (zh) 2005-09-14
CA2395459C (en) 2011-11-01
TR200401396T4 (tr) 2004-08-23
DE50014553D1 (de) 2007-09-20
CY1106977T1 (el) 2012-09-26
NO331317B1 (no) 2011-11-21
PT1244434E (pt) 2004-08-31
ZA200205027B (en) 2004-03-08
WO2001045679A2 (de) 2001-06-28
CA2395459A1 (en) 2001-06-28
CN101513405B (zh) 2012-07-04
ES2291583T3 (es) 2008-03-01
EP1244434A2 (de) 2002-10-02
JP2004501063A (ja) 2004-01-15
CN100488950C (zh) 2009-05-20
NO20023026L (no) 2002-08-20
DE50005742D1 (de) 2004-04-22
NO20071958L (no) 2002-08-20
NO20023026D0 (no) 2002-06-21
WO2001045679A3 (de) 2002-07-18
AU2171601A (en) 2001-07-03
ATE369344T1 (de) 2007-08-15
MXPA02006248A (es) 2002-12-05
CA2717246C (en) 2014-02-11
DE19962470A1 (de) 2001-07-12
US20160045490A1 (en) 2016-02-18
EP1408034B1 (de) 2007-08-08
BR0017041A (pt) 2002-10-22
DK1244434T3 (da) 2004-07-19
DK1408034T3 (da) 2007-12-17
US20070197501A1 (en) 2007-08-23
US20030045544A1 (en) 2003-03-06
ES2218264T3 (es) 2004-11-16
EP1244434B1 (de) 2004-03-17
US20100330165A1 (en) 2010-12-30
CN101513405A (zh) 2009-08-26
KR100803442B1 (ko) 2008-02-13
PL205148B1 (pl) 2010-03-31
ES2291583T5 (es) 2011-09-29

Similar Documents

Publication Publication Date Title
IL150359A0 (en) Use of chemotherapeutic agents
CA2121230A1 (en) 1,3-dihydro-2h-imidazo(4,5-b) quinolin-2-one derivatives
MY119254A (en) 1, 3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives
IL123655A (en) Substituted tetracyclic tetrahydrofuran derivatives and pharmaceutical compositions containing them
ATE186301T1 (de) An den positionen 2 und 9 substituierte 4h-pyrido-(1,2-a)pyrimidin-4-one
DE3750668D1 (de) 7-[3-(Aminomethyl)-3-alkyl-1-pyrrolidinyl]chinolin-3-carbonsäure-Derivate und diese enthaltende pharmazeutische Zusammensetzungen.
JPH01316321A (ja) ギラーゼ抑制因子の筋肉注射剤
NO852026L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive bis -(4-aminofenyl)-sulfoner.
DK132188A (da) Anvendelse af tetrahydrobenz(c,d)indol-6-carboxamider som anxiolytika
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
PT947513E (pt) Derivados de amina triciclicos
DE3464603D1 (en) 2-anilino-1,6-dihydro-6-oxo-5-pyrimidinecarboxylic acid derivatives, processes for the preparation thereof, and antiallergic agent containing the same
KR970703147A (ko) 동맥경화 억제제(Arteriosclerosis Depressant)
JPH06166623A (ja) 抗菌性組成物
EP2266566A3 (en) Nicotinamide derivatives and their use as therapeutic agents
ES8407057A1 (es) Un procedimiento para la preparacion de un derivado de cefalosporina.
BG103985A (en) Multicyclic derivatives of erythromycin
TH19844A (th) ????????????????????????????????????????????????? ?5-(n-??????????????????? ??????) ???????????????????
NL7510483A (en) Alpha-ureido-thienylacetamido-cephalosporanic acids - with broad-spectrum antibacterial activity for oral or parenteral admin., for disinfection and as additives for animal feeds